- Issue price
- ₹43per share
- Issue size
- ₹11.61 Cr27,00,000 shares
- Face value
- ₹10per equity share
- Lot size
- 3,000 sharesMin. ₹1.29 L at the upper price
- Anchor biddingMon, 2026
- OpensTue, 2026
- ClosesThu, 2026
- AllotmentMon, 2026
- ListingTue, 2026
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue
- Fresh issue
- 27,00,000 shares (₹11.61 Cr)
- Offer for sale
- None
- Total issue
- 27,00,000 shares (₹11.61 Cr)
- Market maker portion
- 1,38,000 shares
- Face value
- ₹10
- Listing at
- BSE SME
Source: ProspectusUpdated
Reservation
Share of the total issue- Retail33.3%
- Anchor27.1%
- QIB ex-anchor20.0%
- Small NII9.6%
- Big NII4.9%
- Market maker5.1%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | 9,00,000 | 35.13% | 35% |
| Non-institutional investors (NII) | 3,90,000 | 15.22% | 15% |
| Small NII (₹2–10 lakh) | 2,58,000 | 10.07% | — |
| Big NII (above ₹10 lakh) | 1,32,000 | 5.15% | — |
| Qualified institutional buyers (QIB) | 12,72,000 | 49.65% | 50% |
| QIB, excluding anchor | 5,40,000 | 21.08% | — |
| Anchor investors | 7,32,000 | 28.57% | — |
| Market maker | 1,38,000 | — | — |
Source: ProspectusUpdated
Lot size
Amounts at ₹43 per share| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail individual investors | 2 | 6,000 | ₹2.58 L |
Source: ProspectusUpdated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2024-25- EPS (basic)
- ₹4.1
- P/E (FY 2024-25 at cap price)
- 10.49×
- NAV per share (March 31, 2025)
- ₹12.38
- RoNW
- 27.37%
Source: ProspectusUpdated
Financials
Standalone, restated · ₹ crore| Period ended | 31 Dec 20259 months | 31 Mar 2025FY 2024-25 | 31 Mar 2024FY 2023-24 | 31 Mar 2023FY 2022-23 |
|---|---|---|---|---|
| Revenue from operations | 21.41 | 28.06 | 23.57 | 19.85 |
| Total income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit after tax | 2.22 | 2.83 | 1.80 | 0.26 |
| Net worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and surplus | 3.65 | 1.64 | 3.76 | 2.08 |
| Total assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
FY 2024-25 vs FY 2023-24: revenue +19.1%, profit after tax +57.0%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: ProspectusUpdated
About the company
The company markets pharmaceutical products under the 'Goldline' brand across five product segments. It does not manufacture the products itself and instead uses contract manufacturers and distributors to supply the market.
- Incorporated
- 2004
- Industry
- Pharmaceuticals
- CIN
- U51397MH2004PLC147806
- Website
- goldlinepharma.in
Source: ProspectusUpdated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Amol Laxmikant Mujumdar | 39.85% | — |
| Swapan Premprakash Khandelwal | 39.85% | — |
Source: ProspectusUpdated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Repayment of all or part of certain outstanding borrowings | 8.35 |
| General corporate purposes | 1.71 |
Source: ProspectusUpdated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Goldline Pharmaceutical LimitedIssuer | ₹4.1 | 10.49× | 27.37% | ₹12.38 |
| Mono Pharmacare Limited | ₹1.75 | 7.57× | 9.90% | ₹17.66 |
| Chandra Bhagat Pharma Limited | ₹1.14 | 28.94× | 2.86% | ₹39.72 |
Source: ProspectusUpdated
Strengths and risks
Our summary of what the offer document statesStrengths
- Long-standing promoters with extensive experience in pharmaceutical marketing and supply chain.
- Asset-light model that relies on contract manufacturers rather than owned plants.
- Diversified portfolio of products across five therapy-focused segments.
- Established distribution network serving wholesalers and retailers across several states.
Risks
- Relies entirely on third-party contract manufacturers for all products, exposing it to their quality, delivery and capacity lapses.
- Customer concentration is high, with top 10 customers accounting for most of revenue.
- Significant borrowings and high debt-to-equity ratio in past years.
- Contingent liabilities from contested income tax and indirect tax demands.
- Promoter group entities operate in a similar line of business, creating potential conflicts.
Source: ProspectusUpdated
Documents
Contacts
Source: ProspectusUpdated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Allotment
- Listing
Source: ProspectusUpdated
After listing
Listing price, day-one high and low, and the change from the issue price (₹43) appear here after the shares list on BSE SME.
Work out the gain or loss on allotted shares after charges and tax →
Frequently asked questions
When does the Goldline Pharmaceutical IPO open and close?
According to the Prospectus, the issue opens on Tuesday, 12 May 2026 and closes on Thursday, 14 May 2026.
What is the Goldline Pharmaceutical IPO price band?
The final issue price is ₹43 per share.
What is the lot size of the Goldline Pharmaceutical IPO?
One lot is 3,000 shares, which is ₹1.29 L at ₹43 per share.
Where will Goldline Pharmaceutical shares list?
On BSE SME. The tentative listing date is Tuesday, 19 May 2026.
Who is the registrar of the issue?
Bigshare Services Private Limited (SEBI registration INR000001385). Allotment status is checked on the registrar's website.
How do I check the Goldline Pharmaceutical IPO allotment status?
The basis of allotment is expected to be finalised on Monday, 18 May 2026. After that, search by PAN, application number or DP/client ID on the registrar's website (Bigshare Services Private Limited) or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹8.35 Cr for repayment of all or part of certain outstanding borrowings, ₹1.71 Cr for general corporate purposes.
Related IPOs
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.